HypGen Inc
Change company Symbol lookup
Select an option...
HPGN HypGen Inc
IX Orix Corp
WHR Whirlpool Corp
PG Procter & Gamble Co
PWJAX PGIM Jennison International Opportunities Fund- Class A
MBWM Mercantile Bank Corp
MEIUF Meitu Inc
HD Home Depot Inc
ACC American Campus Communities Inc
MRLN Marlin Business Services Corp
Go

Company profile

HypGen Inc., formerly Mega Bridge Inc., is a clinical-staged biotechnology company. The Company through its platform is focused on development and commercialization of Phorbol 12-myristate 13-acetate (PMA) internal i.d. RP-323, a focused immunotherapy and stem cell activator for treating neurological diseases (CNS). The Company is entering into phase II clinical study for developing treatments for neurological and Parkinson’s disease at cellular level. Parkinson’s disease is a progressive, degenerative neurological disease, resulting from degeneration of neurons in a region of the brain that controls movement.

Closing Price
--
Day's Change
--
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
0

GameStop appoints Elliott Wilke to role of chief growth officer

6:45 am ET March 30, 2021 (MarketWatch)
Print
	

(END) Dow Jones Newswires

March 30, 2021 06:45 ET (10:45 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.